Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer can predict whether they are likely to ...
Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States A total of 355 plasma samples were ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...
Retrospective analysis of ctDNA results from real-world data was performed for 61 patients (233 plasma time points) diagnosed with early-stage UC. ctDNA status and dynamics were assessed using a ...
Study to evaluate clinical utility of ctDNA-guided treatment escalation for CRC patients; results expected to read out in mid-2024 AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global ...
CHARLOTTE, N.C. — Circulating tumor DNA (ctDNA) from patients with gastrointestinal (GI) cancers can reflect treatment response, spare some additional treatment, or signal potential remission in those ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study ...
Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results